HTG2014-Section-Header-publications

Categories

Filter by Topics

1L therapy; bispecific antibodies 478P TA-ness AACR2023 ABC- type ADCC Gene Alteration adolescents AI alcohol consumption ALK alzheimer's Angiogenesis angiosarcoma Anti-TNF Alpha Therapy antibody drug conjugates antiEGFR aplastic anemia AA apoptosis Apoptosis appendiceal neoplasms Asthma Autocrine Signaling Autoimmune Disorder Avelumab B Cells B-accute lyphoblastic leukemia B-ALL B-accute lyphoblastic seukemia B-ALL B-cell lymphoma bacterial vaginosis BCL2A1 BCL6 benign bile acids Biofluid Biology of neoplasia Biomarker biomarker Biomarker Analysis Biomarker Discovery Biomarker Validation biomarkers Biomarkers Bladder Bladder Cancer Bladder cancer Blastic plasmacytoid dandritic cell neoplasm BPDCN blastoid morphology blindness Blood bone Brain Breast Cancer breast cancer Breast Milk Breast milk Burkitt lymphoma cancer genetics Cancer Genomics cancer therapy CAR T cell therapy CAR-T-cells Cardiovascular Disease Castleman Disease CD10 CD3 CD8 CDK CDK46 inhibitors CDKN1A CDKN2A mutation Cell Free Plasma Cells Cerebrospinal Fluid cervix Cetuximab Chemokines chemotherapy Childhood Atopic Dermatitis children chronic kidney disease Chronic Obstructive Pulmonary Disease Circulating miRNAs circulating tumor Circulating tumor cells classifications Clinical Trial clinical trial cMET cognition cold tumor Colon Colon cancer Colorectal cancer Comparative Study Comparison study computational toxicology Core Needle Biopsy cornea COVID-19 cultivated limbal epithelial cells Clec Custom mRNA custom panel CXCL12 cyclic AMP‑dependent transcription factor ATF‑4 Cytokine Cytokines Cytotoxic T Cells cytotoxicity Dementia dementia Developmental Immunotherapy Developmental Therapeutics Diabetes diabetic nephropathy Differential Expression Differential Gene Expression Analysis Diffuse Large B-Cell Lymphoma diffuse large B-cell lymphoma DLBCL DLBCL COO DNA damage‑inducible transcript 3 protein DNA lymphoma Drug Response Drug Safety Drug sensitivity Drug Targets Drug-induced Liver Injury dysbiosis Dysplasia ear Efficacy EGFR Muatations EHE cancer EMT Encephalophy end stage kidney disease Endothelial cell EPCORE NHL-1 epidemiology epidermal growth factor receptor EGFRHER Epigenetics epigenomics Epithelial–mesenchymal plasticity Epstein-Barr ERBB3 Esophageal Cancer estrogen and progesteron receptors estrogen receptor 1 ESR1 exosome Exosomes extracellular miRNAs Extracellular Vesicles Extracellular Vesicles Evs extraction-free RNA workflow Fabry Disease farnesoid X receptorcholesterol Feasibility female reproductive tract FFPE FGF Ligand Trap FGFR fibroblast growth factor receptor 4 Fibrous Tumors FOLFOX7 Follicular lymphoma gastrointestinal cancer GEIS Gene Expression gene expression Gene expression analysis Gene Expression Profiling gene expression profiling gene expression signature Gene Fusions Gene Signature Analysis Genetic Polymorphism Genitourinary cancer Glioblastoma Tumors glucocorticoid receptor NR3C1 HARMONIA clinical trial HCC Head and Neck Cancer Head and neck cancer Heart hematologic or solid tumors hepatocellular carcinoma HER HER-2 HER2 HER2- Heterogeneity Histone Deacetylase Inhibitors histone methyltransferase HLA-E Homing hot tumor HPV HR+ HTG EdgeSeq HTG EdgeSeq ALKPlus Assay EU HTG EdgeSeq Custom Assays HTG EdgeSeq DLBCL Cell of Origin Assay HTG EdgeSeq DLBCL Cell of Origin Assay EU HTG EdgeSeq DLBCL Cell of Origin Panel HTG EdgeSeq DLBCL-COO-CE-IVD HTG EdgeSeq EGFR KRAS and BRAF Mutation Assay HTG EdgeSeq Immune Response Panel HTG EdgeSeq Immuno-Oncology Assay HTG EdgeSeq Immuno-Oncology Panel HTG EdgeSeq Lung Fusion Assay HTG EdgeSeq Lymphoma Panel HTG EdgeSeq miRNA Whole Transcriptome Assay HTG EdgeSeq miRNA Whole Transcriptome Panel HTG EdgeSeq miRNA WTA HTG EdgeSeq Mouse mRNA Tumor Response Panel HTG EdgeSeq Oncology Biomarker Panel HTG EdgeSeq PATH Assay HTG EdgeSeq Path Assay HTG EdgeSeq Precision Immuno-Oncology Panel HTG EdgeSeq Precision Immunol-Oncology Panel HTG EdgeSeq System HTG EdgeSeq System Oncology Biomarker Panel HTG EdgSeq Immuno-Oncology Assay HTP ibrutinib Ibrutinib Immune Cells Immune Checkpoint Inhibitors Immune microenvironment Immune Related Genes Immune Response Immune System Immune Tolerance Immune-related Colitis Immuno-Oncology immuno-oncology agents immunohistochemistry IHC Immunologically hot tumours IMMUNOSARC immunoscore immunotherapy Immunotherapy Inflammation inhibitor Insulin Resistance Integrins Intrinsic subtypes inverted papilloma IOA- 244 IOA-244 IRF4 IRP IRS-1 ISG JAVELINE bladder Juvenile Arthritis Kidney kikuchi-fujimoto disease KRAS Kruppel-like factor 5 Lactobacillus crispatus LAG3+ Limb ischemia limbal stem cell deficiency LSCD Liposarcoma Liquid Biopsy Liver liver liver disease liver steatosis liver tissue Lung Lung cancer lungs Lupus Lymph Node Metastasis lymphatic Lymphocytes Lymphoid Neoplasia lymphoma Lymphoma lymphomas machine learning Machine Learning malignancy sinonasal malignant mCRC Mechanism of Action Melanoma melanoma Mesothelioma MET metastatic breast cancer MBC metastatic colorectal cancer CRC Method Comparison MIBC Microenvironment MicroRNA microRNA miR-122-5p miR-3937 miRNA miRNA WTA miRNA-375 Molecular Characterization molecular subtypes Mouse Mouse mRNA mouse mRNA TRP mRNA mRNA custom mTOR pathway mTOR signaling multi-omics Multiple Myeloma multiple myeloma MUM1 Muscle Muscle-invasive bladder cancer mutation analysis Mutations MYC NAFLD Nash and Fibrosis native African men Natural Killer Cells Nature Neoantigens Nestin+ Neuroendocrine Tumor Neurologic nivolumab NKG2A Non-alcoholic fatty liver disease non-Hodgink Lymphoma non-Hodgkin Lymphoma Non-Hodgkin lymphoma NHL Non-small cell lung cancer Novel Therapeutic Targets NTRK1 nuclease protection assay obesity Obesity OBP Oesophageal Adenocarcinoma Oncology Oncology-Biomarker OPSCC Optical imaging Oral cancer Oral Cancer Oral cavity Oral lesion Oral Squamous Cell Carcinoma oral squamous cell carcinoma Oropharyngeal Cancer OSCC Osteoarthritis Osteoclast Ovarian cancer palbociclib PALLET PALOMA PALOMA-2 PAM50 Predictive biomarkers Pan-Cancer PanB Pancreas Pancreatic Cancer pancreatic ductal adenocarcinoma PDAC Paralysis Parkinson's Disease Partial EMT Pathogenesis pathophysiology Pathway Analysis Pathway analysis Patient Stratification PAXgene PBMCs PCA Cell Lines PD-1 PD-L1 PDX model PEARL PENELOPE-B PFAS PFNA PFOS Phase III PHOENIX trial PI3K PI3K inhibitors PIK3CA mutation PIP placenta Placenta Plasma Plasma miRNAs Platform Comparison PMAIP1 population based Precision medicine Precision oncology predictive biology Predictive Biomarkers Predictive Modeling Prevotella bivia Programmed cell death protein 1 Progression free-survival progression of renal failure Prostate prostate cancer Prostate Cancer prostate genomics Protein Protein Interaction network qNPA qPCR R-CHOP race disparities Radioimmunotherapy RAS Rbsig Rearrangements Refractory DLBCL Relapsed DLBCL Renal Cell Carcinoma renal cell carcinoma Renal Disease Reproductive Response rate RET Reveal Rhabdomyosarcoma RMS Rheumatoid Arthritis Risk Score ROS1 safety Sarcoma sarcoma SARS-CoV-2 scoring system Sequencing Serum Signaling Inhibitors Signaling Pathways Signature Validation Signatures single cell Single-cell RNA Sinonasal Carcinoma Skin soft tissue sarcoma SPECS Lung Consortium squamous cell carcinoma Squamous cell carcinoma STAT6 pathway STD Sub-typing surface plasmon Surveillance Survival Outcomes Survival plots Synovial Fluid Synovial Sarcoma synthetic miRNA T cells T-Cell T-cells targeted therapeutics Technology Comparison Testicular cancer Therapeutic Response Therapeutic targets Thymic Carcinoma Thyroid Cancer Tislelizumab tislelizumab TMB TME tomentosin Toxicity TP53 mutation transcriptome Transcriptome transcriptome profile transcriptome profiling Translational Medicine Transplantation Treatment Outcome Treatment Stratification Treatment Targets Trichomonas vaginalis Triple Negative Breast CancerTNBC Tumor Biology Tumor Heterogeneity Tumor Immunobiology Tumor infiltrating lymphocytes tumor microenvironment Tumor Microenvironment Urine Urothelial carcinoma Uterus vagina VEGFR vestibular schwannoma VS virus Waldeyer's ring Wound healing Xenograft Tissue Zanubrutinib Zanubrutinlb ZEB1

2021

Palbociclib combined with endocrine treatment in breast cancer patients with high relapse risk after neoadjuvant chemotherapy: Subgroup analyses of premenopausal patients in PENELOPE-B.

Marmé, F., et al. Palbociclib combined with endocrine treatment in breast cancer patients with high relapse risk after neoadjuvant chemotherapy: Subgroup analyses of premenopausal patients in PENELOPE-B. J Clin Oncol 39, 2021 (suppl 15; abstr 518). DOI 10.1200/JCO.2021.39.15_suppl.518

View External Link

MamaPred: A new and innovative approach to determine recurrence risk in HR+/HER2- early-stage breast cancer using HTG EdgeSeq technology.

Jose Antonio Lopez Guerrero, et al. MamaPred: A new and innovative approach to determine recurrence risk in HR+/HER2- early-stage breast cancer using HTG EdgeSeq technology. J Clin Oncol 39, 2021 (suppl 15; abstr 558) DOI 10.1200/JCO.2021.39.15_suppl.558

View External Link

Gene expression profiling signatures for immunophenotyping of tumor microenvironment using HTG EdgeSeq Precision Immuno-Oncology Panel.

Jaramillo, M. C., et al. Gene expression profiling signatures for immunophenotyping of tumor microenvironment using HTG EdgeSeq Precision Immuno-Oncology Panel. J Clin Oncol 39, 2021 (suppl 15; abstr e14528). DOI: 10.1200/JCO.2021.39.15_suppl.e14528

View External Link

Palociclib in combination with endocrine therapy versus capecitabine in hormonal receptor-positive, human epidermal growth factor 2-negative, aromatase

Martin, M., et al. Palociclib in combination with endocrine therapy versus capecitabine in hormonal receptor-positive, human epidermal growth factor 2-negative, aromatase. Annals of Oncology, Volume 32, Issue 4, April 2021, Pages 427-430

Download pdf 529KB

A DNA damage repair gene-associated signature predicts responses of patients with advanced soft-tissue sarcoma to treatment with trabectedin

Moura, D. S., et al. A DNA damage repair gene-associated signature predicts responses of patients with advanced soft-tissue sarcoma to treatment with trabectedin. Molecular Oncology 13May2021  https://doi.org/10.1002/1878-0261.12996

Download pdf 14.1MB

Pre-pregnancy BMI-associated miRNA and mRNA expression signatures in the placenta highlight a sexually-dimorphic response to maternal underweight status

Clark, J., et al. Pre-pregnancy BMI-associated miRNA and mRNA expression signatures in the placenta highlight a sexually-dimorphic response to maternal underweight status. Scientific Reports (2021) DOI: 10.21203/rs.3.rs-478026/v1

Download pdf 761KB

Hyperglycemia Regulated Circulating MicroRNAs and Their Effects on Renal Function Decline in Type 2 Diabetes

Kobayashi, H., et al. Hyperglycemia Regulated Circulating MicroRNAs and Their Effects on Renal Function Decline in Type 2 Diabetes.  J Endocr Soc. 2021 May 3; 5(Suppl 1): A414. Published online 2021 May 3. doi: 10.1210/jendso/bvab048.845

View External Link

A bivariate Bayesian framework for simultaneous evaluation of two candidate companion diagnostic assays in a new drug clinical trial.

Richard M. Simon & Songbai Wang (2021) A bivariate Bayesian framework for simultaneous evaluation of two candidate companion diagnostic assays in a new drug clinical trial, Biostatistics & Epidemiology, DOI: 10.1080/24709360.2021.1913705

View External Link

Distal mediator-enriched, placental transcriptome-wide analyses illustrate the Developmental Origins of Health and Disease

Bhattacharya, A. et al. Distal mediator-enriched, placental transcriptome-wide analyses illustrate the Developmental Origins of Health and Disease. medRxiv APR 14, 2021. doi: https://doi.org/10.1101/2021.04.12.21255170. Pre-print

Download pdf 1.9MB

Integrative Clinical, Molecular, and Computational Analysis Identify Novel Biomarkers and Differential Profiles of Anti-TNF Response in Rheumatoid Arthritis

Luque-Tevar, M., et. Al. Integrative Clinical, Molecular, and Computational Analysis Identify Novel Biomarkers and Differential Profiles of Anti-TNF Response in Rheumatoid Arthritis. Front. Immunol., 23 March 2021 | https://doi.org/10.3389/fimmu.2021.631662

Download pdf 3.8MB

Genomic, Transcriptomic, and Functional Alterations in DNA Damage Response Pathways as Putative Biomarkers of Chemotherapy Response in Ovarian Cancer

Saha, S. S., et. al. Genomic, Transcriptomic, and Functional Alterations in DNA Damage Response Pathways as Putative Biomarkers of Chemotherapy Response in Ovarian Cancer. Cancers 2021, 13(6), 1420; https://doi.org/10.3390/cancers13061420

Download pdf 3.1MB

Page last updated May 22, 2023